Jan-Per Wenzel, Raed Abdessadok, Sascha Hatahet, Charlotte Eitel, Julius Nikorowitsch, Roman Mamaev, Sorin Popescu, Samuel Reincke, Anna Traub, Behnam Subin, Suzanne de Waha, Tanja Zeller, Karl-Heinz Kuck, Roland Richard Tilz
{"title":"Balloon vs. balloon-comparison of hemolysis and renal markers after cryoballoon vs. ballon-in-basket pulsed field pulmonary vein isolation.","authors":"Jan-Per Wenzel, Raed Abdessadok, Sascha Hatahet, Charlotte Eitel, Julius Nikorowitsch, Roman Mamaev, Sorin Popescu, Samuel Reincke, Anna Traub, Behnam Subin, Suzanne de Waha, Tanja Zeller, Karl-Heinz Kuck, Roland Richard Tilz","doi":"10.3389/fcvm.2025.1681098","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Single-shot ablation systems are widely used for pulmonary vein isolation (PVI) in atrial fibrillation (AF). Cryoballoon ablation (CBA) ablation is a well-established thermal method, while balloon-in-basket pulsed field ablation (BiB-PFA) represents a novel non-thermal modality. Both may elicit systemic effects, including hemolysis and renal stress. This study aimed to compare biomarker changes indicative of hemolysis and renal function following CBA vs. BiB-PFA.</p><p><strong>Methods: </strong>In this prospective, non-randomized, single-center study, patients undergoing first-time PVI with either CBA or BiB-PFA were enrolled. Venous blood samples were collected before PVI and at day 1 post procedure. Laboratory analyses included lactate dehydrogenase (LDH), haptoglobin, hemoglobin, myoglobin, total bilirubin, creatinine, and estimated glomerular filtration rate (eGFR).</p><p><strong>Results: </strong>A total of 100 patients were included (CBA: <i>n</i> = 50; BiB-PFA: <i>n</i> = 50). Acute and first-pass PVI was achieved in all cases. CBA resulted in a significantly greater increase in LDH (Δ+60 vs. + 47 U/L; <i>p</i> = 0.038) and a more pronounced decline in haptoglobin (Δ-13 vs. -3 mg/dl; <i>p</i> = 0.003). Hemoglobin decreased after BiB-PFA (Δ-0.62 g/dl) but slightly increased after CBA (Δ+0.18 g/dl; <i>p</i> < 0.001). Myoglobin and bilirubin changes were comparable. There was no significant difference in kidney function change between the groups (CBA: Δ-2.0 vs. BiB-PFA: glomerular filtration rate -1.0 ml/min; <i>p</i> = 0.522).</p><p><strong>Conclusion: </strong>While CBA was associated with more pronounced hematologic changes, kidney function did not differ between groups. These findings emphasize the systemic effects of catheter design and energy modality while supporting the renal safety of both techniques.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1681098"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479498/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1681098","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims: Single-shot ablation systems are widely used for pulmonary vein isolation (PVI) in atrial fibrillation (AF). Cryoballoon ablation (CBA) ablation is a well-established thermal method, while balloon-in-basket pulsed field ablation (BiB-PFA) represents a novel non-thermal modality. Both may elicit systemic effects, including hemolysis and renal stress. This study aimed to compare biomarker changes indicative of hemolysis and renal function following CBA vs. BiB-PFA.
Methods: In this prospective, non-randomized, single-center study, patients undergoing first-time PVI with either CBA or BiB-PFA were enrolled. Venous blood samples were collected before PVI and at day 1 post procedure. Laboratory analyses included lactate dehydrogenase (LDH), haptoglobin, hemoglobin, myoglobin, total bilirubin, creatinine, and estimated glomerular filtration rate (eGFR).
Results: A total of 100 patients were included (CBA: n = 50; BiB-PFA: n = 50). Acute and first-pass PVI was achieved in all cases. CBA resulted in a significantly greater increase in LDH (Δ+60 vs. + 47 U/L; p = 0.038) and a more pronounced decline in haptoglobin (Δ-13 vs. -3 mg/dl; p = 0.003). Hemoglobin decreased after BiB-PFA (Δ-0.62 g/dl) but slightly increased after CBA (Δ+0.18 g/dl; p < 0.001). Myoglobin and bilirubin changes were comparable. There was no significant difference in kidney function change between the groups (CBA: Δ-2.0 vs. BiB-PFA: glomerular filtration rate -1.0 ml/min; p = 0.522).
Conclusion: While CBA was associated with more pronounced hematologic changes, kidney function did not differ between groups. These findings emphasize the systemic effects of catheter design and energy modality while supporting the renal safety of both techniques.
背景与目的:单次消融系统被广泛用于房颤(AF)的肺静脉隔离(PVI)。低温球囊消融(CBA)是一种成熟的热方法,而球囊内脉冲场消融(BiB-PFA)则代表了一种新的非热方式。两者均可引起全身影响,包括溶血和肾应激。本研究旨在比较CBA与BiB-PFA治疗后溶血和肾功能的生物标志物变化。方法:在这项前瞻性、非随机、单中心研究中,纳入了首次接受PVI的CBA或BiB-PFA患者。在PVI术前和术后第1天采集静脉血样本。实验室分析包括乳酸脱氢酶(LDH)、触珠蛋白、血红蛋白、肌红蛋白、总胆红素、肌酐和估计的肾小球滤过率(eGFR)。结果:共纳入100例患者(CBA: n = 50; BiB-PFA: n = 50)。所有病例均获得急性和首过期PVI。CBA导致LDH显著升高(Δ+60 vs + 47 U/L, p = 0.038),而触珠蛋白下降更为明显(Δ-13 vs -3 mg/dl, p = 0.003)。BiB-PFA后血红蛋白降低(Δ-0.62 g/dl), CBA后略有升高(Δ+0.18 g/dl; p p = 0.522)。结论:虽然CBA与更明显的血液学改变相关,但两组之间肾功能没有差异。这些发现强调了导管设计和能量方式的系统影响,同时支持两种技术的肾脏安全性。
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.